U.S. flag

An official website of the United States government, Department of Justice.

In Vitro Structure-activity Relationships and Forensic Case Series of Emerging 2-benzylbenzimidazole 'Nitazene' Opioids

NCJ Number
309693
Journal
Archives of Toxicology Volume: 98 Issue: 9 Dated: September 2024 Pages: 2999-3018
Date Published
September 2024
Length
20 pages
Annotation

This paper provides a systematic comparison of the impact of different structural alterations to the nitazene core structure on µ-opioid receptor activity; it reports on a study that examined the in vitro functional characterization of a comprehensive set of 25 differentially substituted nitazenes at MOR, using a β-arrestin 2 recruitment assay and an intracellular cyclic adenosine monophosphate assay; it also discusses the prevalence of those nitazene opioids, geographical distribution, and toxicological findings.

Abstract

2-Benzylbenzimidazole ‘nitazene’ opioids are presenting a growing threat to public health. Although various nitazenes were previously studied, systematic comparisons of the effects of different structural modifications to the 2-benzylbenzimidazole core structure on μ-opioid receptor (MOR) activity are limited. Here, the authors assessed in vitro structure–activity relationships of 9 previously uncharacterized nitazenes alongside known structural analogues. Specifically, they focused on MOR activation by ‘ring’ substituted analogues (i.e., N-pyrrolidino and N-piperidinyl modifications), ‘desnitazene’ analogues (lacking the 5-nitro group), and N-desethyl analogues. The results from two in vitro MOR activation assays (β-arrestin 2 recruitment and inhibition of cAMP accumulation) showed that ‘ring’ modifications overall yield highly active drugs. With the exception of 4′-OH analogues (which are metabolites), N-pyrrolidino substitutions were generally more favorable for MOR activation than N-piperidine substitutions. Furthermore, removal of the 5-nitro group on the benzimidazole ring consistently caused a pronounced decrease in potency. The N-desethyl modifications showed important MOR activity, and generally resulted in a slightly lowered potency than comparator nitazenes. Intriguingly, N-desethyl isotonitazene was the exception and was consistently more potent than isotonitazene. Complementing the in vitro findings and demonstrating the high harm potential associated with many of these compounds, the authors describe 85 forensic cases from North America and the United Kingdom involving etodesnitazene, N-desethyl etonitazene, N-desethyl isotonitazene, N-pyrrolidino metonitazene, and N-pyrrolidino protonitazene. The low-to-sub ng/mL blood concentrations observed in most cases underscore the drugs’ high potencies. Taken together, by bridging pharmacology and case data, this study may aid to increase awareness and guide legislative and public health efforts. (Published Abstract Provided)

Date Published: September 1, 2024